AngioDynamics Files 8-K on Financials
Ticker: ANGO · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001275187
| Field | Detail |
|---|---|
| Company | Angiodynamics Inc (ANGO) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 8-k, reporting
Related Tickers: ANGI
TL;DR
ANGI dropped an 8-K on 4/2/26 covering financials. Check exhibits for deets.
AI Summary
On April 2, 2026, AngioDynamics Inc. filed an 8-K report detailing results of operations and financial condition. The filing includes various exhibits, such as financial statements and presentations, indicating a review of the company's performance. Specific financial figures and operational details are expected to be found within the attached documents.
Why It Matters
This filing provides investors with crucial updates on AngioDynamics' financial performance and operational status, enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate indication of significant negative events.
Key Players & Entities
- ANGIODYNAMICS INC (company) — Filer
- 0001275187 (company) — CIK Number
- 0001140361-26-012891 (filing) — SEC Accession Number
- 2026-04-02 (date) — Filing Date and Period of Report
FAQ
What specific financial results are detailed in this 8-K filing?
The filing indicates 'Results of Operations and Financial Condition' under Item 2.02, with detailed information expected within the attached exhibits like EX-99.1 and EX-99.2.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026, at 07:30:58.
What types of exhibits are included with this 8-K filing?
The filing includes exhibits such as 'EX-99.1' and 'EX-99.2', which appear to be financial statements and presentations, along with graphic files likely related to the presentations.
What is the primary purpose of an 8-K filing like this one?
An 8-K filing is used to report significant events that shareholders should be aware of, such as material changes in financial condition or operations.
Where is AngioDynamics Inc. located based on the mailing address provided?
The mailing address listed is 14 PLAZA DRIVE.
Filing Stats: 965 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2026-04-02 07:30:58
Key Financial Figures
- $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select
Filing Documents
- ef20069681_8k.htm (8-K) — 31KB
- ef20069681_ex99-1.htm (EX-99.1) — 1073KB
- ef20069681_ex99-2.htm (EX-99.2) — 27KB
- ef20069681_ex99-2slide1.jpg (GRAPHIC) — 81KB
- ef20069681_ex99-2slide2.jpg (GRAPHIC) — 275KB
- ef20069681_ex99-2slide3.jpg (GRAPHIC) — 164KB
- ef20069681_ex99-2slide4.jpg (GRAPHIC) — 107KB
- ef20069681_ex99-2slide5.jpg (GRAPHIC) — 100KB
- ef20069681_ex99-2slide6.jpg (GRAPHIC) — 127KB
- ef20069681_ex99-2slide7.jpg (GRAPHIC) — 151KB
- ef20069681_ex99-2slide8.jpg (GRAPHIC) — 139KB
- ef20069681_ex99-2slide9.jpg (GRAPHIC) — 183KB
- ef20069681_ex99-2slide10.jpg (GRAPHIC) — 27KB
- ef20069681_ex99-2slide11.jpg (GRAPHIC) — 180KB
- ef20069681_ex99-2slide12.jpg (GRAPHIC) — 197KB
- ef20069681_ex99-2slide13.jpg (GRAPHIC) — 207KB
- ef20069681_ex99-2slide14.jpg (GRAPHIC) — 83KB
- ef20069681_ex99-2slide15.jpg (GRAPHIC) — 176KB
- 0001140361-26-012891.txt ( ) — 4339KB
- ango-20260402.xsd (EX-101.SCH) — 4KB
- ango-20260402_lab.xml (EX-101.LAB) — 21KB
- ango-20260402_pre.xml (EX-101.PRE) — 16KB
- ef20069681_8k_htm.xml (XML) — 4KB
02 – Results of Operations and Financial Condition
Item 2.02 – Results of Operations and Financial Condition. On April 2, 2026, AngioDynamics, Inc. ("AngioDynamics") issued a press release announcing financial results for the fiscal third quarter ended February 28, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 – Regulation FD Disclosure
Item 7.01 – Regulation FD Disclosure. Presentation slides discussing AngioDynamics and its fiscal third quarter ended February 28, 2026 are furnished herewith as Exhibit 99.2. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act.
Forward-Looking Statements
Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, tariffs, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects
01 – Financial Statements and Exhibits
Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release, dated April 2, 2026. 99.2 Presentation, dated April 2, 2026. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: April 2, 2026 By: /s/ Lawrence T. Weiss Name: Lawrence T. Weiss Title: Senior Vice President, Chief Legal Officer and Corporate Secretary